University of Rhode Island   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Kingston RI United States (1892)

Organization Overview

First Clinical Trial
2009
NCT01342445
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

University of Rhode Island

Active Ingredients

Drugs in Phase 4 Trials (1)

lisdexamfetamine (vyvanse) (1 trial)

Drugs in Phase 3 Trials (3)

buprenorphine (2 trials)

naloxone (narcan) (2 trials)

naltrexone (revia) (2 trials)

Drugs in Phase 2 Trials (1)

treprostinil (remodulin) (1 trial)

Drugs in Phase 1 Trials (2)

dabigatran (pradaxa) (1 trial)

pf-5190457 (1 trial)

Drugs in Other Trials (2)

permethrin (nix) (1 trial)

pomegranate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcohol Drinking (Phase 1)

Alcoholism (Phase 1)

Alcohol-Related Disorders (Phase 1)

Alzheimer Disease (Phase 1)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Cognitive Dysfunction (Phase 1)

Delayed Graft Function (Phase 2)

Ischemia (Phase 2)

Reperfusion Injury (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9